ReviewAnnals of translational medicine2026
A developmentally informed narrative review of Toll-like receptors in adult and pediatric acute respiratory distress syndrome.
Review in Annals of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Acute respiratory distress syndrome (ARDS) is a severe inflammatory lung syndrome associated with high mortality and morbidity. Toll-like receptors (TLRs), key pattern-recognition receptors of innate immunity, mediate inflammatory responses to both infectious and sterile lung injury. Although TLR signaling has been increasingly implicated in ARDS pathogenesis, significant developmental and translational gaps remain, particularly in pediatric ARDS (PARDS). This review summarizes current evidence on TLR-mediated mechanisms in ARDS and PARDS, with emphasis on developmental regulation and translational relevance. Methods: A narrative review was conducted using English-language studies identified from PubMed/MEDLINE and Google Scholar databases. Experimental, translational, and clinical studies investigating TLR signaling in ARDS and PARDS were reviewed, including studies involving cell-surface and endosomal TLRs, developmental immunology, animal models, genetic and transcriptomic analyses, and therapeutic modulation of TLR pathways or their key effector cytokines. Key Content and Findings: TLR4 is an extensively studied receptor in ARDS, mediating inflammatory responses to endotoxins, sterile injury, sepsis, and ventilator-induced lung injury (VILI) through MyD88- and TRIF-dependent pathways. Endosomal TLRs, including TLR3, TLR7, and TLR9, contribute predominantly to viral-induced lung injury and antiviral immunity. Experimental studies demonstrate that TLR activation drives cytokine amplification, neutrophil recruitment, endothelial dysfunction, and alveolar-capillary barrier disruption. Human studies identify TLR-associated polymorphisms and transcriptomic alterations linked to ARDS susceptibility and outcomes. Importantly, pediatric immune responses exhibit developmental regulation of TLR signaling, with age-dependent variation in receptor expression and cytokine production, suggesting PARDS pathogenesis involving TLR activation cannot be directly inferred from adult disease models. However, direct TLR-focused studies in PARDS remain limited. Conclusions: TLR signaling pathways are central to ARDS and PARDS pathogenesis and represent potential therapeutic targets. However, direct evidence in PARDS remains limited. Future research should prioritize age-stratified pediatric studies to define developmental differences in TLR signaling and guide therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.